Author

Joshua S. Lichtman

Observed names: J. Lichtman, Joshua Lichtman, Joshua S Lichtman, Joshua S. Lichtman

Observed institutions: NGM Biopharmaceuticals (United States), Stanford Medicine, Stanford University

ORCID: 0000-0002-5256-6773

Observed ORCID: 0000-0002-5256-6773

OpenAlex ID: A5068847926

Seasonal cycling in the gut microbiome of the Hadza hunter-gatherers of Tanzania

2017 · Samuel A. Smits, Jeff Leach, et al. · Science · 892

Quantitative Imaging of Gut Microbiota Spatial Organization

2015 · Kristen A. Earle, Gabriel Billings, et al. · Cell Host & Microbe · 427

LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor

2017 · Xuecai Ge, Hong Yang, et al. · Cell Metabolism · 386

Role of disease-associated tolerance in infectious superspreaders

2014 · Smita Gopinath, Joshua S. Lichtman, et al. · Proceedings of the National Academy of Sciences · 87

Host-Microbiota Interactions in the Pathogenesis of Antibiotic-Associated Diseases

2016 · Joshua S. Lichtman, Jessica A. Ferreyra, et al. · Cell Reports · 84

The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2021 · Kevin J. Paavola, Julie M. Roda, et al. · Cancer Immunology Research · 70

A mutation rate model at the basepair resolution identifies the mutagenic effect of polymerase III transcription

2023 · Vladimir Seplyarskiy, Evan M. Koch, et al. · Nature Genetics · 67

Host-centric Proteomics of Stool: A Novel Strategy Focused on intestinal Responses to the Gut Microbiota

2013 · Joshua S. Lichtman, Angela Marcobal, et al. · Molecular & Cellular Proteomics · 57

Monitoring host responses to the gut microbiota

2015 · Joshua S Lichtman, Justin L Sonnenburg, et al. · The ISME Journal · 44

The effect of microbial colonization on the host proteome varies by gastrointestinal location

2015 · Joshua S Lichtman, Emily Alsentzer, et al. · The ISME Journal · 32

550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors

2021 · R. Jain, E.J. Kim, et al. · Annals of Oncology · 4

Abstract LB216: Pre-clinical characterization of NGM831, an ILT3 antagonist antibody for the treatment of solid tumors

2022 · Peirong Chen, Suzanne C. Crawley, et al. · Cancer Research · 3

Evaluation of an anti-IL33 x anti-TSLP bispecific antibody, CMT-133, as a novel therapeutic for respiratory inflammation

2026 · Janet Y. Leung, Edward Yang, et al. · European Respiratory Journal

Data from The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2023 · Kevin J. Paavola, Julie M. Roda, et al.

Supplementary Figure from The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2023 · Kevin J. Paavola, Julie M. Roda, et al.

Supplementary Table from The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2023 · Kevin J. Paavola, Julie M. Roda, et al.

Supplementary Figure from The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2023 · Kevin J. Paavola, Julie M. Roda, et al.

Supplementary Table from The Fibronectin–ILT3 Interaction Functions as a Stromal Checkpoint that Suppresses Myeloid Cells

2023 · Kevin J. Paavola, Julie M. Roda, et al.

Quantifying dynamic host‐microbiota signatures of antibiotic‐associated GI infection: What can the host proteome tell us?

2015 · Joshua Elias, Joshua Lichtman, et al. · The FASEB Journal

Works count: 19

Citation count: 2,153

H-index: 10

I10-index: 10